Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Elger; Walter
Address:
Berlin, DE
No. of patents:
111
Patents:


1 2 3










Patent Number Title Of Patent Date Issued
RE39862 Unsaturated 14, 15-cyclopropanoandrostanes, a method for their production and pharmaceutical com September 25, 2007
The invention relates to new unsaturated 14,15-cyclopropano-androstanes of the general formula (I) ##STR00001## to their synthesis and to pharmaceutical compositions, containing these compounds.The compounds of formula (I) have gestagenic and/or androgenic activity.
8193252 Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hor June 5, 2012
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibr
7732493 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17.beta.-hydroxy steroid dehydroge June 8, 2010
The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I ##STR00001## in which R.sup.2 means a C.sub.1-C.sub.8-alkyl group, a C.sub.1-C.sub.8-alkyloxy group or a halogen atom, R.sup.13 means a hydrogen atom or a methyl group, R.sup.17 means a
7629334 Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone r December 8, 2009
The use of mesoprogestins as pharmaceutical components for the manufacture of a medicament for hormone replacement therapy (HRT) and as components for the combined use together with an estrogen for the manufacture of a medicament for HRT as well as in respective HRT-methods and methods o
7550451 Progesterone receptor modulators with increased antigonadotropic activity for female birth contr June 23, 2009
The invention relates to new compounds of general formula I, ##STR00001## their production and pharmaceutical preparations that contain these compounds.The compounds according to the invention are preferably used for female birth control and for HRT.
7534780 Estradiol prodrugs May 19, 2009
The invention relates to estradiol prodrugs of general formula (I), in which group Z is bonded to the steroid, ##STR00001## process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with e
7507725 Compounds with sulphonamide group and pharmaceutical compositions containing these compounds March 24, 2009
The invention relates to compounds which, acting as a prodrug and/or support, enable an active agent to be taken up by the erythrocytes and/or an active agent to bind to the erythrocytes. The uptake of these compounds by and/or the binding thereof to the erythrocytes is made possible
7435757 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17.beta.-hydroxy steroid dehydroge October 14, 2008
The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I ##STR00001## in which R.sup.2 means a C.sub.1-C.sub.8-alkyl group, a C.sub.1-C.sub.8-alkyloxy group or a halogen atom, R.sup.13 means a hydrogen atom or a methyl group, R.sup.17 means a
7419972 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17.beta.-hydroxy steroid dehydrogen September 2, 2008
The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I ##STR00001## as well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for prophylaxis and/or therapy of estrogen-dependent diseases that can be influe
7388003 .DELTA..sup.15-D-Homosteroids with androgenic action June 17, 2008
The invention relates to .DELTA..sup.15-D-homosteroids of general formula (I) ##STR00001## process for their production and pharmaceutical compositions that contain these compounds.The compounds of general formula I according to the invention have androgenic activity.
7378404 8.beta.-hydrocarbyl-substituted estratrienes for use as selective estrogens May 27, 2008
This invention describes the new 8.beta.-substituted estratrienes of general formula I in which R.sup.2, R.sup.3, R.sup.6, R.sup.6', R.sup.7, R.sup.7', R.sup.9, R.sup.11, R.sup.11', R.sup.12, R.sup.14, R.sup.15, R.sup.15', R.sup.16, R.sup.16', R.sup.17 and R.sup.17' have the meanings
7335650 Composition February 26, 2008
There is provided a pharmaceutical composition comprising (i) a compound of the formula ##STR00001## wherein: X is a hydrocarbyl ring having at least 4 atoms in the ring; K is a hydrocarbyl group; Rs is a sulphamate group; (ii) optionally admixed with a pharmaceutically acceptable c
7297702 Contraception method using competitive progesterone antagonists and novel compounds useful there November 20, 2007
Competitive progesterone antagonists, including two novel steroids, viz., 11.beta.,19-[4-(cyanophenyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-h- ydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11.beta.,19-[4-(3-pyridinyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-h- ydroxyprop-1(Z)-en
7199115 17.alpha.-fluorosteroids, pharmaceutical compositions containing 17.alpha.-fluorosteroids and a April 3, 2007
New 17.alpha.-fluorosteroid compounds of formula (I) are disclosed: ##STR00001## wherein R.sup.1 denotes H or methyl; R.sup.2 and R.sup.3 each denote H, Cl or methyl; and either a double bond or a single bond is present between C-6 and C-7 and also C-9 and C-10 of the steroid ring s
7186728 Methylene-4-azasteroids March 6, 2007
17-methylene-4-azasteroid compounds of formula I: ##STR00001## wherein R.sup.20 denotes fluoro, chloro or bromo R.sup.20a denotes hydrogen, R.sup.10 and R.sup.4 each denote a hydrogen atom or a methyl group, and R.sup.1 and R.sup.2 each denote a hydrogen atom or together denote an a
7053077 Use of biogenic estrogen sulfamates for hormone replacement therapy May 30, 2006
The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of
6956031 11.beta.-Substituted 19-nor-17-.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-l October 18, 2005
This invention relates to new 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring with a long-chain substituent in 11.beta.-position of general formula II ##STR1##in which R.sup.11 is a long-chain alkyl radical that has a nitrogen atom that can b
6894038 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases May 17, 2005
The invention relates to the use of esters of estriol, for example, an estriol 3,17-dipropionate or an estriol 3,17-dihexanoate, for the treatment of autoimmune diseases, such as multiple sclerosis (MS).
6855836 17-Methylene steroids, process for their production and pharmaceutical compositions that contain February 15, 2005
The invention relates to 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds.The compounds according to the invention have a hybrid-type profile of action in the sense that they act as inhibitors of 5.alpha.-reductase and simul
6841548 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives January 11, 2005
The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formulaThe preparations according to the invention can be used for hormonal contraception and for hormon replacement therapy (HRT). Th
6825182 17.alpha.-fluoroalkyl-11.beta.-benzaldoxime steroids, process for their production, pharmaceutic November 30, 2004
Compounds of general formula I as well as their pharmaceutically compatible salts are described, in which R.sub.1 stands for hydrogen, C.sub.1 - to C.sub.6 -alkyl, COR.sub.4, COOR.sub.4, COSR.sub.4 or CONHR.sub.5, in which R.sub.4 is C.sub.1 - to C.sub.6 -alkyl or unsubstituted or substi
6790853 Contraception method using competitive progesterone antagonists and novel compounds useful there September 14, 2004
Competitive progesterone antagonists, including two novel steroids, viz., 11.beta.,19-[4-(cyanophenyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl)-4-androsten-3-one and 11.beta.,19-[4-(3-pyridinyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl
6723715 14, 15-cyclopropanosteroids of the 19-norandrostane series, method for producing said compounds April 20, 2004
The invention relates to the new 14,15-cyclopropanoandrosteroids of the 19-norandrostane series of the general formula (I) ##STR1##their synthesis and to pharmaceutical compositions containing these compounds.The compounds of formula (I) have an interesting, mixed androgen/gestagen p
6710039 Unsaturated 14,15-cyclopropane-androstanes, a method for their production and pharamceutical com March 23, 2004
The invention relates to new unsaturated 14,15-cyclopropano-androstanes of the general formula (I) ##STR1##to their synthesis and to pharmaceutical compositions, containing these compounds.The compounds of formula (I) have gestagenic and/or androgenic activity.
6670347 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring December 30, 2003
This invention relates to new 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring of formula II, ##STR1##process for their production and pharmaceutical preparations that contain these compounds as well as 17.alpha.-cyanomethylated estra-1,3,5(10
6653298 Composition November 25, 2003
Disclosed and claimed are methods for oral contraception, or a hormone replacement therapy, or for treating breast cancer, in a patient in need thereof involving administering to the patient, at a dosage of no greater than 200 .mu.g/day per 70 kg subject, a compound having Formula (I):
6608074 Contraception method using competitive progesterone antagonists and novel compounds useful there August 19, 2003
Competitive progesterone antagonists, including two novel steroids, viz., 11.beta.,19-[4-(cyanophenyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl)-4-androsten-3-one and 11.beta.,19-[4-(3-pyridinyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl
6583130 C13-substituted estra-1,3,5,(10)-trien-3-yl sulfamates, methods of preparing same, and pharmaceu June 24, 2003
The invention relates to new C.sub.13 -substituted estra-1,3,5(10)-trien-3-yl sulfamates of general formula I, ##STR1##wherein R.sub.1 represents an acyl residue, oxycarbonyl residue, aminocarbonyl residue, sulfonyl residue, or aminosulfonyl residue, and R.sub.15 represents ethyl, me
6569844 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives May 27, 2003
The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formulaat their C3 position wherein R is a R.sup.1 R.sup.2 N group wherein R.sup.1 and R.sup.2 are independent of each other and rep
6534490 Unsaturated 14, 15-cyclopropanoandrostanes, method for the production thereof and pharmaceutical March 18, 2003
Described are new, unsaturated 14,15-cyclopropano-androstanes of general formula (I) and their pharmaceutically acceptable salts, a process for their production and pharmaceutical preparations that contain these compounds. The compounds are characterized by hormonal (gestagenic and/or
6436917 Non-estrogenic estradiol derivative compounds with anti-oxidative activity August 20, 2002
New non-estrogenic derivative compounds of estradiol, which have no estrogenic activity and comparatively high anti-oxidative activity, are disclosed. These new non-estrogenic derivative compounds are potentially useful as non-estrogenic antioxidants, especially for administration in
6388109 14,15-cyclopropano steroids of the 19-norandrostane series, method for the production thereof an May 14, 2002
Described are new 14,15-cyclopropano steroids of the 19-norandrostane series of general formula (I) and their pharmaceutically acceptable salts, a process for their production and pharmaceutical preparations that contain these compounds. The compounds are distinguished by hormonal (g
6365582 S-substitute 11.beta.-benzaldoxime-estra-4, 9-diene-carbonic acid thiolesters, method for the pr April 2, 2002
Thiol esters of S-substituted 11.beta.-benzaldoxime-estra-4,9-dien-carboxylic acids of the formula I ##STR1##their pharmaceutically acceptable salts, a method for their synthesis and pharmaceutical preparations containing these compounds are described. These compounds bind to progest
6340688 Contraception method using competitive progesterone antagonists and novel compounds useful there January 22, 2002
Competitive progesterone antagonists, including two novel steroids, viz., 11.beta.,19-[4-(cyanophenyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl)-4-androsten-3-one and 11.beta.,19-[4-(3-pyridinyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl
6225347 9-halogen-(Z)-prostaglandin derivatives, process for their production and their use as pharmaceu May 1, 2001
The invention relates to 9-halogen-(Z) prostane derivatives of formula I ##STR1##in which ##STR2##Z represents the radicalsHal represents a chlorine or fluorine atom in the alpha or beta position,R.sub.1 represents the radical ##STR3##with R.sub.2 meaning a hydrogen atom, an alkyl, cyclo
6080735 Estra-1,3,5(10)-trien derivatives, processes for their preparation and pharmaceutical compositio June 27, 2000
This invention is relating to new estra-1,3,5(10)-trien-sulfamates carrying at the 3-position an R--SO.sub.2 --O--group, with R being an R.sup.1 R.sup.2 N--group in which R.sup.1 and R.sup.2, independently of each other, represent a hydrogen atom, an alkyl residue with 1-5 C atoms or,
5891910 9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceu April 6, 1999
The invention relates to 9-halogen-(Z) prostane derivatives of formula I ##STR1## in which ##STR2## Z represents the radicals Hal represents a chlorine or fluorine atom,R.sub.1 represents ##STR3## A represents a --CH.sub.2 --CH.sub.2 --, a trans--CH=CH or --C.ident.C, W r
5843933 11.beta.-aryl-4-estrenes, process for their production as well as their use as pharmaceutical ag December 1, 1998
Compounds of formula I ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings indicated in the description, are described, as well as processes for their production, pharmaceutical preparations containing these compounds as well as their use for treatment of
5843931 6,7-modified 11.beta.-aryl-4-oestrenes December 1, 1998
Compounds of the general formula I ##STR1## are described, in which x represents an oxygen atom or the hydroxyimino grouping >N.about.OH,R.sup.1 represents a hydrogen atom or a methyl group,G represents a hydrogen atom, a halogen atom or a C.sub.1 -C.sub.4 -alkyl radical, when M a
5795881 Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epo August 18, 1998
A pharmaceutical agent contains a progesterone synthesis inhibitor (ProI) of the trilostane or epostane type and an antigestagen (AG). It can be used for inducing delivery at term in humans and animals, for terminating normal or pathological pregnancies therein or for treatment of ho
5744464 Antigestagens for the inhibition of uterine synthesis of prostaglandin April 28, 1998
Antigestagens inhibit prostaglandin synthesis by the uterus and thus can be used to treat symptoms of dysmennhorea.
5728689 11.beta.-aryl-4-estrenes, process for their production as well as their use as pharmaceutical ag March 17, 1998
A method of inducing an antigestagenic effect by the administration of compounds of formula I: ##STR1## wherein, substituents are as defined in the specification.
5705495 Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pha January 6, 1998
The invention relates to new sulfamate derivatives of 1,3,5(10)-estratriene derivatives of the general formula I ##STR1## wherein the 3-sulfamate moiety is acylated, sulfonated or amidosulfonated. Furthermore, methods for the production of the compound and pharmaceutical preparat
5693628 11-benzaldoxime-estra-diene derivatives, methods for their production and pharmaceuticals contai December 2, 1997
This invention relates to new 11-benzaldoxime-estra-diene derivatives of the general formula I ##STR1## and their pharmaceutically acceptable salts, a method for their production, and pharmaceuticals containing such compounds.The compounds described show strong antigestagenic effects
5614213 Use of estriol for treatment of climacteric osteoporosis March 25, 1997
The invention relates to the use of estriol as the sole active ingredient for the production of a transdermal medicament which continuously releases the active ingredient for the treatment of climacteric osteoporosis. It has been shown according to the invention that estriol, which has u
5576310 11-benzaldoxime-17.beta.-methoxy-17.alpha.-methoxymethyl-estrasdiene derivatives, methods for th November 19, 1996
This invention relates to new 11-benzaldoxime-estra-diene derivatives of the general formula I ##STR1## wherein Z is --CO--CH.sub.3, --CO--O--C.sub.2 H.sub.5, --CO--NH-phenyl, --CO--NH--C.sub.2 H.sub.5, --CO--C.sub.2 H.sub.5, --CH.sub.3, or --CO-phenyland their pharmaceutically a
5569652 Dihydrospirorenone as an antiandrogen October 29, 1996
Dihydrospirorenone, ##STR1## preferably together with an estrogen, can be used for the production of a pharmaceutical agent suitable for treatment of hormonal irregularities during premenopause (menstruation stabilization), for hormonal substitution therapy during menopause, for
5529993 14.alpha., 17.alpha.-ethano-16.alpha.-hydroxy-estratrienes June 25, 1996
A 14.alpha.,17.alpha.-bridged estratriene of formula I ##STR1## wherein (a) OR.sup.3 is in .alpha.-positionR.sup.1, R.sup.2 and R.sup.3, each independently are (i) hydrogen, (ii) ##STR2## in which R.sup.4 is an organic radical with up to 11 carbon atoms or (iii) --(CH.sub.2).sub
5519027 D-homo-(16-ene)-11.beta.-aryl-4-estrenes, process for their production as well as their use as p May 21, 1996
New D-homo-(16-ene)-11.beta.-aryl-4-estrenes of general formula I ##STR1## as well as their pharmaceutically compatible addition salts with acids are described in whichX stands for an oxygen atom, the hydroxyimino grouping >N.about.OH or two hydrogen atoms,R.sup.1 stands for a hyd
5491137 14.alpha.17.alpha.-(Propano-and 17.sup.2 propeno) -estratrienes February 13, 1996
14.alpha.,17.alpha.-(Propano-and 17.sup.2 -propeno)-estratrienes of general formula I ##STR1## in which R.sup.1 means a hydrogen atom, a methyl or an acyl group with 1-12 carbon atoms,R.sup.2 means a hydrogen atom or an acyl group with 1-12 carbon atoms and ##STR2## a C--C si
1 2 3










 
 
  Recently Added Patents
Controller
Check weigher comprising of a rotating weighing chute with an accumulating and a discharge position that calculates flow rate by measuring weight accumulated during a predetermined time interv
Alterable account number
Storage system with LU-setting function
Secure device sharing
Video stabilization
Washing-up bowl
  Randomly Featured Patents
Method of producing resin solution and a suspension of particles therein for use as a starting material for the manufacture of a coated filler powder for making molds and the like
Drive device
Circuit module for multi-pin connector
USB connector
Anthurium plant named `Saskia`
Parasitic helminth PLA2 proteins and nucleic acid molecules
Photographic processing apparatus with variable sized tanks lined with bag-like plastic tank interiors
Internal combustion engine with starter device
4-aryl-2-anilino-pyrimidines
Hair harvesting device and method with localized subsurface dermal fluid insertion